symposium handbook - az659834.vo.msecnd.net

2019 The Cutting Edge of O&G 1

2019 The Cutting Edge of O&GRANZCOG SA/NT

Saturday 29 June 2019 | National Wine Centre of Australia, Adelaide

SymposiumHandbook


2019 The Cutting Edge of O&G

Contents

Welcome 3

Scientific Program 4

Symposium Dinner 5

Meeting Points 5

Sponsors & Exhibitors 6

Abstracts 9

ranzcog.edu.au

All information in this booklet is for general reference only. While every effort is made to maintain its currency and accuracy, this document reflects information available at the time of its preparation and currency should be determined having regard to other available information.

Copyright © 2019 | Royal Australian and New Zealand College of Obstetricians and Gynaecologists | All rights reserved.


Welcome

On behalf of the SA/NT Regional Committee we welcome you to attend the RANZCOG SA/NT 2019 The Cutting Edge of O&G Symposium which is being held on Saturday 29th June 2019 at The National Wine Centre, Australia, Adelaide.

The meeting theme The Cutting Edge of O&G offers a thought-provoking program. We hope that many of you will be able to take the time to enjoy what our program has to offer, and also join us in the evening at the symposium dinner.

We are grateful to the invited interstate speakers and those dedicated speakers from our specialty who have kindly given their time, knowledge and support to this symposium.

We cordially welcome and sincerely thank all the support received from representatives from industry. Support of continuing education is at the core of quality healthcare delivery to women in which we value all sponsors’ support and contributions. We encourage you to take this opportunity to visit the exhibition to learn of products and services that are available to you to assist you in your daily practice. Morning and afternoon teas and lunches will be held in the exhibition area.

Our program commences on Saturday morning at 8.30am with registration and the first session commencing at 9.00am Ultrasound/MRI.

We look forward to seeing you at the symposium.

Yours sincerely

Dr Michael McEvoy, Convenor

RANZCOG SA/NT 2019 The Cutting Edge of O&G

2019 The Cutting Edge of O&GRANZCOG SA/NT

Saturday 29 June 2019 | National Wine Centre of Australia, Adelaide


Saturday 29th June 2019

08.30 Registration and Welcome

Session One Chair – Dr Julie Grant

09.00–09.25 Ultrasound/MRI Jane Woolcock

09.25–09.50 Surgical Challenges Amy Hercus

9.50–10.15 Placental Pathology Nick Manton

10.15–10.40 Clinical Applications & Discussions Amanda Poprzeczny

10.40–11.00 Morning Tea

Session Two Chair – Dr Michael McEvoy

11.00–11.30 How to Avoid AHPRA Notification Fiona Sinnamon/Matt Hardy

11.30–12.00 Free Communications

12.00–12.30 Hypothetical: What is Informed Consent in O&G? Anthony Mennillo/Michael McEvoy

12.30–13.30 Lunch

Session Three Chair – Dr Aimee Wiltshire

13.30–14.20 Endometriosis/Ablation Jason Abbott

14.20–14.29 Free Communications

14.30–15.00 Vulva Surgery Controversies Ann Olsson

15.00–15.30 Afternoon Tea

Session Three Chair – Dr Colin Weatherill

15.30–16.00 Development of an Artificial Womb Sean Carter

16.00–16.30 Prenatal Genetics Tristan Hardy

16.30–17.00 College Update Vijay Roach

17.00–17.30 Training & Ongoing Upskilling of the Gynaecologist Jason Abbott

Scientific Program


Symposium Dinner

The Vines Room & Terrace, National Wine Centre of Australia

19.00 Pre-Dinner Cocktails

19.30 Dinner Commences

20.00 College Grace/Entrée

20.30 Presentation for 35-Year Fellowship

21.00 Main Course

21.45 Presentations for Winner of Free Communications

22.10 Dessert/Coffee/Tea

Meeting PointsThis meeting has been approved as a RANZCOG Approved O&G Meeting and eligible Fellows of this College will earn CPD points for attendance as follows:

Full Attendance: 6 CPD (Clinical Expertise)

RACGP points can be self-claimed/ACRRM points have been applied.


Sponsors & ExhibitorsThe South Australian/Northern Territory Regional Committee acknowledges and sincerely thanks the following companies for their valued contribution and support.

Gold Sponsor

Silver Sponsor


Trade Sponsors

ACLM

AR-B

F-NA

T-02

35.1

05/

19

Obstetrics & Gynaecology Expert PathologySupporting you with Leadership in Science and Pioneering Technology

While our clinical test centres lead the industry in traditional molecular analysis, our genetics laboratories offer a state-of-the-art platform where our expert pathologists focus on a complete testing scope for obstetrics and gynaecology. More than just trustworthy results, our partnership can complement your clinical work by providing support and insight for you to guide your patients towards healthier and happier lives.

Genetic Carrier Screening • Gene Access (CF, FXS, SMA)• Invitae (Comprehensive)• Ashkenazi Panel Screening• Factor V Leiden

Fertility• Anti-Müllerian Hormone (AMH)• Y Microdeletion• Long-term Sperm Storage

Antenatal Screening• Harmony NIPT• Combined First Trimester Screening (cFTS)• Placental Growth Factor (PlGF)

Fertility & Antenatal services offered by Australian Clinical Labs

Disclaimer: HARMONY PRENATAL TEST and HARMONY are trademarks or registered trademarks of Ariosa Diagnostics, Inc. in the U.S.A. and other countries. All other trademarks are the property of their respective owners.

1300 134 111 VIC NSW SA NT

1300 367 674 Western Australia

clinicallabs.com.au

Obstetrics & Gyno Path A4 Advert - ACLMAR-BF-NAT-0235.1.indd 1 16/05/2019 1:52:55 PM


ACLM

AR-B

F-NA

T-02

35.1

05/

19

Obstetrics & Gynaecology Expert PathologySupporting you with Leadership in Science and Pioneering Technology

While our clinical test centres lead the industry in traditional molecular analysis, our genetics laboratories offer a state-of-the-art platform where our expert pathologists focus on a complete testing scope for obstetrics and gynaecology. More than just trustworthy results, our partnership can complement your clinical work by providing support and insight for you to guide your patients towards healthier and happier lives.

Genetic Carrier Screening • Gene Access (CF, FXS, SMA)• Invitae (Comprehensive)• Ashkenazi Panel Screening• Factor V Leiden

Fertility• Anti-Müllerian Hormone (AMH)• Y Microdeletion• Long-term Sperm Storage

Antenatal Screening• Harmony NIPT• Combined First Trimester Screening (cFTS)• Placental Growth Factor (PlGF)

Fertility & Antenatal services offered by Australian Clinical Labs

Disclaimer: HARMONY PRENATAL TEST and HARMONY are trademarks or registered trademarks of Ariosa Diagnostics, Inc. in the U.S.A. and other countries. All other trademarks are the property of their respective owners.

1300 134 111 VIC NSW SA NT

1300 367 674 Western Australia

clinicallabs.com.au

Obstetrics & Gyno Path A4 Advert - ACLMAR-BF-NAT-0235.1.indd 1 16/05/2019 1:52:55 PM

Abstracts

Ultrasound/MRI

9.00am to 9.25am

Dr Jane WoolcockBSc, BMus, BMBS (Hons), FRANZCOG, DDU, COGU

Dr Jane Woolcock is a specialist in obstetrics and gynaecology who has subspecialised in ultrasound. She also has a strong interest in laparoscopic excision of severe endometriosis and pelvic pain.

She trained at Royal Prince Alfred Hospital in Sydney, Royal Darwin Hospital and The Royal Infirmary of Edinburgh before coming to Adelaide, where she has an appointment as a staff specialist at the Women’s and Children’s Hospital and also works privately.

AbstractNot Available at the time of print.

Surgical Challenges

9.25am to 9.50am

Dr Amy HercusFRANZCOG Advanced Trainee & Chief Registrar Flinders Medical Centre

Amy Hercus is an advanced trainee and Chief Registrar at Flinders Medical Centre. She completed her RMO and service year at the Lyell McEwin Hospital before moving to Flinders Medical Centre, and completing rotations through the Women’s and Children’s Hospital and Mt Gambier Hospital.

Amy has a keen interest in high-risk pregnancies, with a particular focus on placental abnormalities and the placenta accreta spectrum. She has been working with Placenta Accreta Team at FMC for several years now, and is hoping to continue to progress her skills both overseas and locally in the coming years.

AbstractDuring this session, we will address some of the major surgical challenges affecting modern obstetrics. We will use a key case from the Flinders Medical Centre Placenta Accreta team to highlight many of the confounding issues that make up our high-risk cohort.

Throughout our discussion, we will address placental abnormalities and the placenta accreta spectrum and major obstetric haemorrhage. We will explore iatrogenic injury prevention, particularly urological, and the role our interventional radiology and vascular colleagues have to play in patients at significantly high risk of caesarean hysterectomy. We will also discuss patient-specific comorbidities that we are seeing with increasing frequency, including increasingly long surgical histories and high BMIs, and the impact of this on both delivery and postnatal recovery.

Our exploration of a single case will highlight the importance and complexity of each of these issues, as well as the benefit of high functioning mutli-disciplinary team work in these settings.


Placental Pathology

9.50am to 10.15am

Dr Nick MantonConsultant Pathologist, Surgical Pathology

I am a Paediatric and Perinatal Pathologist based at the Women’s and Children’s Hospital, Adelaide. My areas of interest include perinatal autopsy pathology, paediatric tumour pathology and placental histopathology. I also have a special interest in perinatal/paediatric neuromuscular pathology.

AbstractThere is an extended list of indications for sending placentas for histopathologic examination. Placental vasculopathy may play a major role in many of these including pre-eclampsia, IUGR, abnormal CTG or fetal loss. Some of the pathological changes in this setting may not only correlate with maternal clinical features, but may be associated with adverse pregnancy outcomes for the baby, including neurodevelopmental outcome. It is clearly important to recognise the importance of placental examination in these settings.

Clinical Applications & Discussions

10.15am to 10.40am

Dr Amanda PoprzecznyFRANZCOG

Amanda graduated from the University of Adelaide in 2010, and commenced O&G training at the Lyell McEwin Hospital in 2013. She cracked an aged bottle of cabernet sauvignon when she achieved her FRANZCOG in 2019, but feels there should have been balloons and trumpets as well. As a glutton for punishment – and because one set of exams is never enough – she commenced training in Maternal Fetal Medicine at the Women’s and Children’s Hospital in 2018. You will currently find her either in a darkened ultrasound room, or consulting multiple textbooks at once, in the hopes of understanding such things as diamniotic trichorionic quadruplets and other unbelievable rarities.

AbstractChronic villitis, massive chronic intervillositis, meconium myonecrosis, placentitis … what do these mean, and what do we do for the woman who sits in front of us when the pathology report comes back? Amanda will aim to unravel some of these terms and their clinical correlations, and discuss the available evidence for antenatal management in subsequent pregnancies.

How to avoid AHPRA notification

11.00am to 11.30am

Matt HardyBio not available at the time of print.

Fiona SinnamonBio not available at the time of print.

AbstractAbstract not available at the time of print.

Medtronic Australasia Pty Ltd2 Alma Road, Macquarie Park, NSW 2113 AustraliaToll Free: 1800 668 670

© Medtronic 2019 All Rights Reserved. EM 1036-03-19 ANZ. #5967-042019

TWO NEWTECHNOLOGIES.SAME BIGADVANTAGE INHYSTEROSCOPY.†

HysteroLux™ Fluid Management System

TruClear™ Elite Hysteroscope

TruClear™ Elite hysteroscopes available in mini and plus sizes

Introducing the latest TruClear™

system advancements for yourhysteroscopy procedures

† Compared to previous generation device

EM 1036-03-19 TruClear AD B&W.indd 1 13/5/19 2:02 pm


Free Communications

A Retrospective Cohort Study of Rheumatic Heart Disease in Pregnancy in a Large Tertiary Centre

11.30 to 11.39am

Dr Robert Carey FRANZCOG Advanced Trainee

I am a current 5th year RANZCOG trainee, AGES fellow and Chief Registrar at Flinders Medical Centre. I have an interest in pursuing minimally invasive surgical techniques, including advanced laparoscopic surgery, and vaginal surgery, while still maintaining general obstetric practice. I enjoy the variety of our practice and the ability to mentor the up-and-coming generation of obstetricans and gynaecologists.

AbstractAuthors: Dr. Robert Carey1, Assoc. Prof. Rosalie Grivell1,2

1 Department of Obstetrics and Gynaecology, Flinders Medical Centre2 College of Medicine and Public Health, Flinders University

Background: Rheumatic heart disease (RHD) is an ongoing contributing factor to maternal morbidity and mortality worldwide. It contributes to the burden of disease for many groups of women of childbearing age and their families.

Aims: To describe the maternal cardiac and obstetric outcomes in pregnant women with RHD who deliver at Flinders Medical Centre.

Methods: A retrospective case note analysis of women with RHD who were referred to Flinders Medical Centre, a state tertiary referral centre for maternal cardiac disease in pregnancy between 2007–2017. We included women who delivered after 20 weeks gestation. Outcomes were analysed for maternal and neonatal outcomes and cardiac interventions.

Results: 50 patients were identified, of which 52% were referred from the Northern Territory (n=26) and 20% from rural South Australia (n=10). 76% women identified as Indigenous Australians (n=38). The most common valvular lesion was mitral stenosis (n=27, 54%), with combined aortic and mitral disease present in 14% of patients (n=7). 26% of patients had undergone prior valvular surgery (n=13). There were no maternal deaths, one neonatal death, one genetic termination and one early intrauterine fetal death. Concurrent pre-eclampsia was present in 14% of patients (n=7). The average gestational age at delivery was 35+3 weeks (95% CI 34+1 weeks to 36+5 weeks).

Conclusion: Although RHD historically has been a major contributor to maternal morbidity and mortality, current management results in low rates of maternal and fetal complications.


DCDEA Twins Complicated by Molar Pregnancy: A Rare Cause of Hyperemesis Gravidarum

11.39 to 11.48am

Dr Caitin LudlowRANZCOG Diplomate

Dr Caitlin Ludlow, prevocational registrar and RANZCOG Diplomate at the Women’s and Children’s Hospital, Adelaide

AbstractLudlow C1, Sam K1, Poprzeczny AJ1,2

1 Department of Obstetrics and Gynaecology, Women’s and Babies Division, Women’s and Children’s Hospital, Adelaide, SA, Australia.

2 Discipline of Obstetrics and Gynaecology, The Robinson Research Institute, the University of Adelaide, Adelaide, SA, Australia.

Introduction: The differential diagnosis of hyperemesis gravidarum is long, and includes multiple pregnancy and gestational trophoblastic disease. We present a case of a DCDA twin pregnancy with a live fetus and complete mole. The reported incidence of such a pregnancy is 1 per 22,000–100,000. Limited data currently exist surrounding these pregnancies, however case reports and series show they are associated with high maternal morbidity. Various ultrasound and biochemical markers can raise suspicion of this abnormality early in the first trimester.

Case: A 30 year old primigravida presented at 14 weeks gestation with persistent nausea & vomiting and per-vaginal bleeding in second trimester of pregnancy. Maternal beta-hCG was 14.89 MoM at first trimester screening. Pelvic ultrasound demonstrated a multi-cystic placenta consistent with a molar pregnancy, and a co-existent live fetus with a separate, apparently normal placenta. Following extensive counselling, the patient underwent a surgical termination of pregnancy. Histopathology confirmed the diagnosis of a complete molar pregnancy with a co-existing DCDA twin.

Discussion: We present a rare differential for hyperemesis gravidarum, and review the outcomes of twin pregnancies complicated by gestational trophoblastic disease. Diagnosis is usually made via ultrasound, however, images may be mistaken as a sub-chorionic haematoma, particularly in setting of one live twin. We will review the ultrasound findings and early pregnancy biochemical and radiological ‘clues’ associated with such a rare cause of hyperemesis gravidarum.


SA Pelvic Mesh Consumer Support Line: A South Australian Experience

11.48 to 11.57am

Dr Ellen RaghoudiFRANZCOG Advanced Trainee

Ellen Raghoudi is in her final year of training and currently working at the Lyell McEwin Hospital. She continues to have a broad interest in obstetrics and gynaecology but has enjoyed the challenge of upskilling in laparoscopy as an advanced trainee. Away from work Ellen enjoys being active, going for walks in the Adelaide hills as well as catching up with friends over a tasty meal and delicious glass of red.

AbstractDr Ellen Raghoudi, Senior Obstetrics & Gynaecology Registrar, Women’s and Children’s Division, Northern Adelaide Local Health Network. Dr Martin Ritossa, Divisional Director, Women’s and Children’s Division, Northern Adelaide Local Health Network. Julie Tucker, RN RM/Midwife Consultant Continence PhD Candidate, Women’s and Children’s Division Northern Adelaide Local Health Network & Robinson Research Institute, School of Medicine, University of Adelaide.

BackgroundIn Australia, a Senate Committee Inquiry was undertaken to review the negative outcomes some women experienced from transvaginal mesh (TVM) used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The inquiry recommended helplines and specialist multi-disciplinary units be established to manage affected women. In response, SA Health established the SA Pelvic Mesh Consumer Support Line.

AimTo report on data gathered from calls to the SA Pelvic Mesh Consumer Support Line to determine the needs of consumers with TVM-related concerns.

MethodA retrospective review of data collected over 10 months since the Support Lines establishment in July 2018. Two senior Continence Nurse Specialists run the Support Line and record data in an Excel spreadsheet containing pre-determined categories and free text. Data includes: baseline TVM information; consumer concern(s); visual analogue scale (VAS) score of concern(s); prior treatment; treatment consumers wish to access, and; call length.

ResultsDuring the study period 175 calls were received. Of these, 31.8% had TVM for POP, 32.4% for SUI, 9.1% for both, while remaining callers were uncertain or had no TVM. Concerns voiced can be grouped into physical, emotional wellbeing, financial, quality of life. The average VAS score was 7.8 (range 0–10). Consumers indicated a need for access to gynaecology and non-gynaecology specialty services as well as allied health.

ConclusionsResults indicate consumer concerns and needs are complex and will provide guidance in the establishment of clinical referral pathways and a dedicated multi-disciplinary TVM clinic for women in South Australia.


Hypothetical: What is informed consent in O&G?

12.00 to 12.30pm

Mr Anthony MennilloManager Claims & Legal Services, MIGA

Anthony Mennillo is a legal practitioner with over 18 years’ experience, specialising in medical negligence and medical disciplinary matters.

Anthony joined MIGA in June 2004 and, as Manager of Claims and Legal Services, provides medico-legal advice to medical practitioners and medical practices across Australia in relation to claims, coronial and disciplinary matters. Anthony takes an active role in the management of claim files, briefing and instructing external panel solicitors. Prior to joining MIGA, Anthony worked with a major legal practice specialising in this area.

Dr Michael McEvoy M.B., B.S., FRANZCOG

Dr Michael McEvoy is a specialist obstetrician and gynaecologist of 34 years standing. His main interests are medicolegal reporting, clinical governance, patient safety and quality, risk management, research and ethics. He is an international medical graduate supervisor, an examiner for RANZCOG, a member of the expert witness panel of RANZCOG, a member of the Australasian Gynaecological Endoscopy and Surgical Society Research Grants Committee, a member of the Southern Adelaide Human Research and Ethics Committee, and a member of the South Australian Health Practitioners Tribunal.

AbstractIn this session a number of case vignettes will be described with medical and legal commentary on the standard of consent taking illustrated in the case record. Mr Anthony Menillo of the Medical Indemnity Group Australia (MIGA) will provide a legal perspective and the audience voting will provide a medical perspective.

Consent issues make up only approximately 10% of medicolegal complaints, but are often highlighted when there is also an adverse outcome or potentially negligent clinical behaviour.

Adequate consent processes, patient information RANZCOG leaflets, diagrams, commentary in letters to general practitioner, satisfactory completion of the consent form, and particular material risks brought up by the patient are all important aspects. Documentation of the conversation between the doctor and the patient outlining benefits and risks is most important.

However, the judgement of what is considered to be informed consent is left to the court to decide in the individual case. Their opinion may be swayed by that of an expert witness as to what is standard accepted professional performance, the quality of the notes, the content of the consent form, but ultimately the judge will decide.

Contemporaneous note keeping, extra attention to the difficult complex enquiring patient, and proof that further information has been given, are all important.

Cases to be discussed include failed sterilisation, ureteric injury at hysterectomy, perforation of the uterus after retained products of conception, and failure to warn of potential stillbirth in a diabetic woman.


Endometriosis/Ablation

13.30 to 14.20pm

Prof Jason AbbottB Med (Hons), FRANZCOG, FRCOG, PhD

Dr Jason Abbott is Professor of Gynaecological Surgery at the University of New South Wales. He is Senior Editor of the Journal of Minimally Invasive Gynaecology an associate editor for ANZJOG and Human Reproduction and has more than 125 publications including text-books, book chapters and large-scale RCTs in gynaecological surgery. Jason has an active role in undergraduate, post-graduate and doctoral supervision and is the former Chairman of the Practice Committee of the AAGL charged with delivering evidence-based guidelines for surgical gynaecology. Jason is the Immediate Past President of AGES, was deputy chair for the ACSQHC’s clinical care standard on heavy menstrual bleeding, chaired the MBS review committee for benign gynaecology and helped shape the National Action Plan for Endometriosis launched by Minister Hunt in July 2018. He is a Principal Investigator and Chair for the MRFF funded NECST network in endometriosis in Australia.

AbstractNot Available at the time of print.

Free Communications

Morbidly Adherent Placenta – An Unexpected Case Managed Conservatively

14.20 to 14.29pm

Dr Anthia RallisFRANZCOG, Women’s and Children’s Hospital, North Adelaide

Dr Anthia Rallis is an obstetrician and gynaecologist working in both the private and public sectors here in Adelaide. In her final years of training she concentrated on acquiring skills in high-risk pregnancy management and generalised gynaecological surgery including advanced laparoscopy.

Anthia has a special interest in high-risk obstetrics and teaching. Her specific areas of expertise include management of vaginal birth after caesarean and vaginal breech delivery, general gynaecology and reproductive health, mature women’s health, laparoscopic surgery, and colposcopy.

AbstractMorbidly Adherent Placenta (MAP) can be diagnosed in up to half of all cases prior to delivery due to high-resolution and Doppler ultrasound as well as adjunctive MRI. This allows planning for management of blood loss and possible peri-partum hysterectomy, both of which have been shown to improve maternal outcomes. Some women, however, request preservation of fertility and conservative management of MAP should be considered. Several case reports and series describe a number of methods for conservative management of MAP, usually in the setting of expected abnormal placentation. Results are varied, but suggest that conservative management is suitable for women who are agreeable to, and have access to, long-term monitoring and follow up.

I describe here a case of conservative management for MAP in a 44-year-old woman who wished to avoid hysterectomy. Placenta increta was unexpectedly diagnosed at her third caesarean section.

The placenta was left in situ almost in entirety and close follow up was employed to ensure the woman did not experience secondary postpartum haemorrhage or endometritis. Removal of the majority of the placenta was possible 127 days postpartum, vaginally. No major bleeding occurred, hysterectomy was not required and the woman recovered well.

Conservative management by leaving the placenta in situ, at delivery, is an option for management of the stable patient, particularly where future fertility is desired.


Vulva Surgery Controversies

14.30 to 15.00pm

Dr Ann Olsson MBBS, FRANZCOG

Dr Ann Olsson is a gynaecologist currently practising in South Australia. She graduated from the University of Adelaide in 1984 and completed specialist training in obstetrics and gynaecology in 1994. She works in both public and private practice in Adelaide and rural South Australia.Her hospital appointment is at Flinders Medical Centre as a Senior Consultant in the Colposcopy and Vulval Clinic.

She is a Past President of the Australian Society for Psychosocial Obstetrics and Gynaecology and the Australian and New Zealand Vulvovaginal Society.

AbstractThis presentation will focus largely on the issues surrounding requests for and provision of labioplasty for young women. A review of the role of laser surgery for vulval conditions will be addressed as well as a brief discussion on Fenton’s operation.

Development of an Artificial Placenta and Uterus

14.30 to 15.00pm

Dr Sean CarterFRANZCOG Trainee

Sean Carter is an Obstetrics & Gynaecology Registrar from Perth, Western Australia currently working at King Edward Memorial Hospital. Between his clinical duties Sean is involved in research in the prevention of preterm birth with the University of Western Australia’s Medical School, under the supervision of Professor John Newnham and Professor Matthew Kemp.

Sean first became involved in clinical research as a medical student working in UWA’s clinical research facility colloquially known as ‘The Sheep Shed’. At present Sean is involved in a collaborative research project which has recently been accepted for publication in the American Journal of Obstetrics and Gynecology. This is a joint project between the University of Western Australia and Tohoku University in Sendai, Japan, investigating the development of an artificial placenta.

When Sean is not in the sheep lab he is particularly fond of drinking a good South Australian Barossa Shiraz after a day’s surfing.

AbstractFirst achievement of successful maintenance in 95 days extremely preterm lambs treated with Ex Vivo Uterine Environment (EVE) Therapy.

Haruo USUDA, MD. Shimpei WATANABE, MD. Masatoshi SAITO, MD, PhD. Shinichi SATO, MD. Gabrielle MUSK, PhD. Erin FEE, MSc,. Sean CARTER, MD. Yusaku KUMAGAI, MD. Tsukasa TAKAHASHI, MD. Shinichi KAWAMURA, Takushi HANITA, MD, PhD. Shigeo KURE MD,PhD. Nobuo Yaegashi MD,PhD . John P NEWNHAM , MD. Matthew W. KEMP, PhD Division of Obstetrics and Gynecology, University of Western Australia, WA, Australia; Center for Perinatal and Neonatal Medicine, TUH, Sendai, Miyagi, Japan; King Edward Memorial Hospital, Perth, WA , Australia.

(Continued overleaf)


Introduction: Ex-vivo uterine environment (EVE) therapy is an experimental neonatal intensive care strategy aimed to reduce the risk of morbidity and mortality for extremely preterm infants born at the border of viability (21–24 weeks gestation). We aimed to use this platform to achieve 120h of healthy survival of 700g/95d gestational age (equivalent to 24 weeks human gestation) lambs. Methods: Eight ewes with singleton pregnancies underwent surgical delivery at 95d gestation (term=150d, estimated weight was ~700g). Fetuses were adapted to EVE therapy and maintained for 120h with constant monitoring of key physiological parameters. Antibiotics and nutrients were provided by continuous infusion. Umbilical artery samples were regularly collected to assess blood gas data and white corpuscle counts. Nine pregnant control animals were euthanised at 100d gestation to allow comparative post-mortem analyses. Data were tested for mean differences with ANOVA.

Results: Seven of eight EVE group fetuses completed 120h of therapy with stable vital signs. There were no significant differences (p>0.05) in final weight, crown rump length and body-weight normalised lung and brain weights or haematological parameters relative to control. Daily blood cultures were negative in all animals. Conclusions: There has been little improvement for preterm infants born at the border of viability for several decades. In the present study, extremely preterm lambs (equivalent to 24 weeks human gestation) were maintained in a stable condition for 120h using our EVE therapy platform. With additional refinement, the data generated by this study may inform a treatment option to improve outcomes for extremely preterm infants.

Prenatal Genetics

16.00 to 16.30pm

Dr Tristan HardyMBBS (Hons) MRepM FRANZCOG, Repromed Fertility Specialist

Dr. Tristan Hardy is a consultant at Repromed and is undertaking training in genetic pathology at SA Pathology. His major interest is in the application of genomic technologies to all areas of reproductive and fetal medicine. He has undertaken research in optimising preimplantation genetic testing for single gene disorders using next generation sequencing technology, and has a subspecialty clinic at Repromed with Dr. Jan Liebelt (Clinical Geneticist) reviewing patients who require preimplantation genetic testing. He also assists the Maternal Fetal Medicine Department at the Women’s and Children’s Hospital, Adelaide with issues relating to prenatal diagnosis and follow up of stillbirth and fetal abnormalities.

AbstractPrenatal diagnosis is addresses the clinical question of whether the fetus has a chromosomal or single gene disorder, for individuals with a known risk of a single gene or chromosomal condition and for those determined to be high risk during pregnancy. Testing may therefore range from detection of a known familial variant to a broader assessment of the fetal genome, without prior knowledge or characterisation of the suspected pathogenic variant. The technology available to examine the fetal genome has undergone rapid change in the past decade, and now ranges from conventional karyotyping and single gene variant detection to whole exome and whole genome sequencing. This presentation will provide an overview of past, current and future approaches to prenatal diagnosis.


College Update

16.30 to 17.00pm

Dr Vijay RoachMBBS MRCOG FRANZCOG, RANZCOG President

Dr Vijay Roach is a specialist obstetrician and gynaecologist with 25 years of experience in both public and private practice in Sydney. He is the President of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) and has been the Chair of the Continuing Professional Development Committee, the Engagement Committee and the Training and Accreditation Committee.

Vijay is directly involved in medical education, lecturing at the Universities of Sydney and Notre Dame. He is also involved in teaching and mentoring medical students at Royal North Shore Hospital, emphasising to students the importance and value of compassion and kindness in medical practice.

Vijay is the former Chairman of Gidget Foundation Australia, a role in which he passionately advocated for those affected by mental health disorders in pregnancy and early parenting. He is committed to raising awareness of the importance of emotional wellbeing, speaking on this topic to students, doctors, community groups and policy makers in Australia and overseas.

Training & Ongoing Upskilling of the Gynaecologist

17.00 to 17.30pm

Prof Jason AbbottB Med (Hons), FRANZCOG, FRCOG, PhD

Dr Jason Abbott is Professor of Gynaecological Surgery at the University of New South Wales. He is Senior Editor of the Journal of Minimally Invasive Gynaecology an associate editor for ANZJOG and Human Reproduction and has more than 125 publications including text-books, book chapters and large-scale RCTs in gynaecological surgery. Jason has an active role in undergraduate, post-graduate and doctoral supervision and is the former Chairman of the Practice Committee of the AAGL charged with delivering evidence-based guidelines for surgical gynaecology. Jason is the Immediate Past President of AGES, was deputy chair for the ACSQHC’s clinical care standard on heavy menstrual bleeding, chaired the MBS review committee for benign gynaecology and helped shape the National Action Plan for Endometriosis launched by Minister Hunt in July 2018. He is a Principal Investigator and Chair for the MRFF funded NECST network in endometriosis in Australia.

AbstractNot available at the time of print.

Save the Date!SWAN VALLEY, WA6-8 MARCH 2020

WA/SA/NT Regional Scientific Meeting

A RANZCOG RSM

Enjoyed the Symposium?

Make sure you save the date for next year’s WA/SA/NT

Regional Scientific Meeting, to be held in WA’s Swan

Valley on the SA long weekend, 6–8 March 2020.

Stay at The Vines Resort, situated in the heart of WA’s

oldest wine region, located only 30 minutes from Perth.

The meeting will feature guest speakers, workshops and

opportunities to present research.

We look forward to welcoming you to the meeting!

symposium handbook - az659834.vo.msecnd.net

Documents